Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01895855 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
A Phase 3 study of Cholera, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 3
- Development phase
- 197
- Enrollment target
- 3
- Study locations
NCT01895855 is a Phase 3 study of Cholera that has completed, run by Bavarian Nordic. The registered enrollment target is 197 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT01895855, a Phase 3 study of Cholera, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 197 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of the study is to determine if PXVX0200 is safe and effective in preventing cholera infection
Conditions Studied
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL PXVX0200
Study Locations (3)
Maryland
- University of Maryland Baltimore - Baltimore
Ohio
- Cincinnati Children'S Hospital Medical Center - Cincinnati
Vermont
- University of Vermont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01895855
The ClinicalTrials.gov registry entry for NCT01895855 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cholera appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01895855 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Ohio, Vermont.
Frequently Asked Questions
What is clinical trial NCT01895855 about?
NCT01895855 is a clinical study titled "Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera". The purpose of the study is to determine if PXVX0200 is safe and effective in preventing cholera infection
What is the current status of trial NCT01895855?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 197 participants. The study started on 2013-09. Estimated completion is 2014-11.
What conditions does trial NCT01895855 study?
This clinical trial studies the following conditions: Cholera.
What interventions are being tested in trial NCT01895855?
The interventions under investigation include: placebo (BIOLOGICAL), PXVX0200 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01895855?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01895855 being conducted?
This trial has 3 study locations across Maryland, Ohio, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.